// App-Quantinova.ai

48 : Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Andreas Hochhaus

  • Michael J. Mauro

  • Philippe Rousselot

  • Tomasz Sacha

  • Moshe Talpaz

  • Charles Chuah

  • Jeffrey H. Lipton

  • Michael W. Deininger

  • Charles A. Schiffer

  • Lori J. Maness

  • James K. McCloskey

  • Valentn Garca Gutirrez

  • Hugues de Lavallade

  • Gabriel Etienne

  • Vickie Lu

  • Shouryadeep Srivastava

  • Gianantonio Rosti

Medical Centers

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • Essen University Hospital, Essen, Germany

  • Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

  • Hospital Mignot University de Versailles Saint-Quentin-en-Yvelines,Paris,Frankreich

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detriot, MI

  • University of Nebraska Medical Center, Omaha, NE

  • The John Theurer Cancer Center at Hackensack Meridian Health,Hackensack,United States

  • Gastroenterology Department. Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Haematological Medicine, Kings College Hospital NHS Foundation Trust, London,

  • Institute Bergonie; Institut National de la Sante et de la Recherche Medicale; Groupe France Intergroupe des Leucemies Myeloides Chroniques, Hopital Haut-Leveque, Pessac, France

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

Locations

  • United States

  • United Kingdom

  • Germany

  • France

  • Poland

  • Singapore

  • Canada

  • Spain

  • Italy

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ponatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II

Study Id's

  • NCT01207440

  • NCT02467270

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved